Journeaux disease (Primary biliary cholangitis) - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 6 min read ✅ Medically reviewed
```html Journeaux Disease (Primary Biliary Cholangitis) – Comprehensive Guide

Overview

Journeaux disease, more commonly known as Primary Biliary Cholangitis (PBC), is a chronic, progressive autoimmune liver disorder. It is characterized by the slow destruction of the small bile ducts within the liver (intra‑hepatic bile ducts), which leads to cholestasis (bile buildup), inflammation, fibrosis, and eventually cirrhosis if left untreated.

Who it affects

  • Predominantly women – about 90 % of cases occur in females.
  • Typical age of diagnosis: 40–65 years, though cases can appear in younger adults.
  • Higher prevalence in people of Northern European descent, but the disease occurs worldwide.

Prevalence

  • Estimated prevalence in the United States: 1‑4 per 10,000 adults (≈ 40,000‑160,000 people)¹.
  • Incidence is rising, likely due to improved awareness and better diagnostic testing.

Symptoms

Symptoms of PBC develop slowly and can be subtle early on. They often reflect cholestasis and the body’s response to chronic inflammation.

Common early symptoms

  • Fatigue – persistent tiredness not relieved by rest; reported by up to 80 % of patients.
  • Pruritus (itchy skin) – especially on the palms, soles, and abdomen; worsens at night.
  • Dry eyes and dry mouth (sicca syndrome) – related to associated autoimmune conditions.

Progressive or later‑stage symptoms

  • Jaundice – yellowing of the skin and sclerae as bilirubin rises.
  • Right‑upper‑quadrant abdominal discomfort – due to liver enlargement.
  • Dark urine and pale stools – result of impaired bile excretion.
  • Ascites or peripheral edema – signs of advanced cirrhosis.
  • Easy bruising/bleeding – low clotting factors from impaired liver synthesis.

Associated autoimmune features

  • Raynaud’s phenomenon – cold‑induced color changes in fingers.
  • Autoimmune thyroid disease, Sjögren’s syndrome, systemic sclerosis – often coexist.

Causes and Risk Factors

PBC is considered an autoimmune disease, meaning the body’s immune system mistakenly attacks its own bile duct cells. The exact trigger is unknown, but research points to a combination of genetic susceptibility and environmental exposures.

Genetic factors

  • Strong association with certain human leukocyte antigen (HLA) alleles, especially HLA‑DR8 and HLA‑DRB1*08.²
  • First‑degree relatives have a 2‑3‑fold higher risk.

Environmental & lifestyle factors

  • History of smoking – smokers have a 1.5‑fold increased risk.
  • Exposure to certain chemicals (e.g., nail polish solvents, cleaning agents) has been suggested, though data are inconsistent.
  • Chronic urinary tract infections have been linked in small studies.

Associated autoimmune diseases

  • Patients with autoimmune thyroiditis, rheumatoid arthritis, or Sjögren’s syndrome are at higher risk of developing PBC.

Diagnosis

Diagnosis relies on a combination of clinical suspicion, blood tests, imaging, and sometimes liver biopsy.

Key laboratory tests

  • Alkaline phosphatase (ALP) – typically 2‑10× the upper limit of normal.
  • Gamma‑glutamyl transferase (GGT) – often elevated.
  • Antimitochondrial antibodies (AMA) – present in ~ 95 % of patients; the most specific serologic marker.
  • Antinuclear antibodies (ANA) and anti‑sp100/ anti‑gp210 – may be present, especially when AMA is negative.
  • Liver function panel (AST, ALT, bilirubin) – may be mildly abnormal early, worsening with disease progression.

Imaging

  • Ultrasound – rules out gallstones or bile duct obstruction; may show a mildly enlarged liver.
  • Magnetic resonance cholangiopancreatography (MRCP) – can demonstrate the lack of large‑duct involvement, supporting a diagnosis of PBC over primary sclerosing cholangitis.

Liver biopsy

Historically required for definitive diagnosis, but now reserved for:

  • AMA‑negative cases where diagnosis is uncertain.
  • Patients with atypical features or rapid progression.

Biopsy shows a characteristic “florid duct lesion” – lymphocytic infiltration and destruction of small bile ducts.

Diagnostic criteria (simplified)

A diagnosis can be made when two of the following three are present:

  1. Elevated ALP (≥1.5× ULN) for > 6 months.
  2. Positive AMA (titer ≥ 1:40) or disease‑specific ANA.
  3. Histologic evidence of nonsuppurative destructive cholangitis.

Treatment Options

The goals of therapy are to halt bile‑duct injury, relieve symptoms, and prevent cirrhosis.

First‑line medication

  • Ursodeoxycholic acid (UDCA) – a hydrophilic bile acid given at 13‑15 mg/kg/day. It improves biochemical markers, slows fibrosis, and prolongs transplant‑free survival in most patients.³

Second‑line options (for UDCA‑non‑responders)

  • Obeticholic acid (OCA) – a farnesoid X receptor (FXR) agonist; 5‑10 mg daily. Shown to further reduce ALP and improve liver histology in trials.4
  • Fibrates (e.g., bezafibrate, fenofibrate) – used off‑label; can lower ALP and improve pruritus.

Symptom‑focused therapies

  • Pruritus – cholestyramine (4–16 g/day), rifampin, naltrexone, or sertraline; dosage titrated to effect.
  • Fatigue – address sleep hygiene, treat anemia or hypothyroidism if present, consider low‑dose modafinil under physician supervision.
  • Osteoporosis prevention – calcium (1,200 mg) & vitamin D (800–1,000 IU) supplementation; DEXA scanning every 2‑3 years.

Liver transplantation

Reserved for end‑stage cirrhosis, refractory symptoms, or hepatocellular carcinoma. 5‑year post‑transplant survival exceeds 80 %.

Lifestyle modifications

  • Stop smoking – reduces disease progression.
  • Limit alcohol intake (≤ 20 g/day for women, ≤ 30 g/day for men) or abstain.
  • Maintain a balanced diet rich in fruits, vegetables, lean protein, and whole grains.
  • Exercise ≥ 150 minutes of moderate‑intensity aerobic activity per week.

Living with Journeaux Disease (Primary Biliary Cholangitis)

While PBC is a chronic condition, many patients lead full, active lives with appropriate management.

Regular monitoring

  • Blood tests (ALP, bilirubin, albumin, INR) every 6‑12 months.
  • Imaging (ultrasound) annually to screen for liver nodules.
  • Bone density scan every 2‑3 years.

Practical daily tips

  1. Medication adherence – set alarms or use weekly pill organizers.
  2. Skin care for pruritus – cool showers, fragrance‑free moisturizers, and loose clothing.
  3. Hydration – aim for 2‑3 L of water daily; helps dilute bile acids that cause itching.
  4. Nutrition – limit saturated fats and simple sugars; incorporate omega‑3 fatty acids (e.g., fatty fish) which may have anti‑inflammatory benefits.
  5. Vaccinations – Hepatitis A & B, annual influenza, COVID‑19, and pneumococcal vaccines as recommended.
  6. Support networks – join PBC patient groups (e.g., PBC Foundation) for shared experiences and updates on research.

Psychosocial wellbeing

Fatigue and itching can affect mood. Consider counseling, mindfulness practices, or support groups. Treat coexisting depression or anxiety promptly.

Prevention

Because genetics play a major role, primary prevention is limited. However, risk can be mitigated:

  • Avoid smoking – counseling and cessation programs are effective.
  • Limit exposure to potential environmental triggers – use protective gloves when handling cleaning solvents or nail polish.
  • Early detection in high‑risk individuals – relatives of PBC patients may benefit from baseline liver enzyme testing and AMA screening.
  • Maintain a healthy weight – obesity can accelerate liver fibrosis.

Complications

If untreated or inadequately managed, PBC can lead to serious sequelae:

  • Cirrhosis – scarring that impairs liver function; may progress to portal hypertension.
  • Portal hypertension – variceal bleeding, ascites, splenomegaly.
  • Hepatocellular carcinoma (HCC) – risk increases once cirrhosis is established; surveillance with ultrasound ± alpha‑fetoprotein every 6 months is recommended.
  • Osteoporosis – chronic cholestasis impairs vitamin D metabolism.
  • Fat‑soluble vitamin deficiencies (A, D, E, K) – can cause night blindness, coagulopathy, or neuropathy.
  • Renal dysfunction – secondary to advanced liver disease.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department immediately if you experience any of the following:
  • Sudden, severe abdominal pain especially in the right upper quadrant.
  • Rapidly worsening jaundice or dark urine with pale stools.
  • Unexplained vomiting that contains blood or looks “coffee‑ground”.
  • Bleeding that does not stop (e.g., gums, nose, or gastrointestinal).
  • Confusion, drowsiness, or a sudden change in mental status (possible hepatic encephalopathy).
  • Severe swelling of the abdomen (ascites) with fever or tenderness – could indicate infection (spontaneous bacterial peritonitis).

These signs may signal liver failure, bleeding varices, or infection, all of which require prompt medical attention.

Sources:

  • 1. Mayo Clinic. Primary biliary cholangitis – epidemiology. https://www.mayoclinic.org
  • 2. Lleo A, et al. “Genetics of primary biliary cholangitis.” Nat Rev Gastroenterol Hepatol. 2020;17:123‑138.
  • 3. European Association for the Study of the Liver (EASL) Clinical Practice Guidelines: PBC, 2017.
  • 4. Mayo MJ, et al. “Obeticholic acid for primary biliary cholangitis.” N Engl J Med. 2016;375:631‑643.
  • 5. CDC. “Vaccines for People with Liver Disease.” https://www.cdc.gov
  • 6. Cleveland Clinic. “Primary Biliary Cholangitis (PBC) – Symptoms, Treatment, and Lifestyle.”
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References